title: Prevention of ocular scarring post glaucoma filtration surgery using the inflammatory cell and platelet binding modulator saratin in a rabbit model.
abstract: CONCLUSIONS
  Late complications can occur with use of current antimetabolites to prevent scarring following glaucoma filtration surgery (GFS). Safer, more targeted, anti-fibrosis agents are sought.
  
  
  OBJECTIVE
  The protein saratin has been shown to exhibit anti-fibrotic and anti-thrombotic properties in response to injury, but had not been used for glaucoma surgery. The goal of this study was to compare the efficacy of saratin with that of the widely accepted mitomycin-C (MMC) in prolonging bleb survival following GFS in the rabbit model. Two saratin delivery routes were compared; a single intraoperative topical application versus a combination of intraoperative topical application with two additional postoperative injections.
  
  
  METHODS
  Twenty-four New Zealand White rabbits underwent GFS and received either intraoperative topical saratin, intraoperative topical saratin plus two injections on post-operative days 4 and 8, balanced saline solution (BSS), or MMC. The bleb tissues and their elevation durations were compared based on clinical and histological findings.
  
  
  RESULTS
  Rabbits receiving topical+injections of saratin had a mean bleb survival of 33.6±8.5 days, significantly higher than the negative BSS controls, which averaged 17.4±6.0 days (p = 0.018). No improvement over BSS was seen for rabbits receiving topical saratin only (15.5±4.8 days, p = 0.749). Rabbits receiving saratin did not develop bleb avascularity and thinning associated with MMC treatment and there were no apparent clinical signs of toxicity.
  
  
  CONCLUSIONS
  Treatment with a single intraoperative topical application plus two additional postoperative injections significantly prolonged bleb elevation comparable to MMC, but without toxicity; however, topical application alone was ineffective.
authors.affiliation: Department of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
authors.forename: Jeff
authors.initials: J
authors.lastname: Min
authors.forename: Zachary L
authors.initials: ZL
authors.lastname: Lukowski
authors.forename: Monica A
authors.initials: MA
authors.lastname: Levine
authors.forename: Craig A
authors.initials: CA
authors.lastname: Meyers
authors.forename: Ashley R
authors.initials: AR
authors.lastname: Beattie
authors.forename: Gregory S
authors.initials: GS
authors.lastname: Schultz
authors.forename: Don A
authors.initials: DA
authors.lastname: Samuelson
authors.forename: Mark B
authors.initials: MB
authors.lastname: Sherwood
mesh_terms: D000287:Administration, Topical; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects; D002921:Cicatrix / Q000209:etiology / Q000517:prevention & control*; D004195:Disease Models, Animal; D005123:Eye / Q000187:drug effects / Q000473:pathology; D005355:Fibrosis / Q000209:etiology / Q000517:prevention & control*; D018463:Filtering Surgery / Q000009:adverse effects*; D005901:Glaucoma / Q000473:pathology / Q000601:surgery*; D006801:Humans; D056965:Injections, Intraocular; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use; D011817:Rabbits; D012471:Salivary Proteins and Peptides / Q000008:administration & dosage* / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D012471:Salivary Proteins and Peptides; C440095:saratin; D016685:Mitomycin